Mount Yale Investment Advisors LLC Sells 189 Shares of Eli Lilly and Company (NYSE:LLY)

Mount Yale Investment Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 4.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,219 shares of the company’s stock after selling 189 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $3,820,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Capital Planning LLC bought a new position in Eli Lilly and Company in the 1st quarter worth $262,000. CHURCHILL MANAGEMENT Corp bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $6,916,000. M&G Plc bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $8,896,000. IPG Investment Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $351,000. Finally, HighPoint Advisor Group LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $9,878,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 442,229 shares of company stock valued at $410,002,456. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Citigroup began coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $921.49 on Friday. The firm’s 50-day moving average price is $895.06 and its 200-day moving average price is $838.32. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company has a market cap of $875.79 billion, a PE ratio of 135.71, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.